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Ocular diseases cause visual impairment and blindness, imposing a devastating impact
on quality of life and a substantial societal economic burden. Many such diseases
lack universally effective pharmacotherapies. Therefore, understanding the mediators
involved in their pathophysiology is necessary for the development of therapeutic
strategies. To this end, the hydrolase activity of soluble epoxide hydrolase (sEH)
has been explored in the context of several eye diseases, due to its implications in
vascular diseases through metabolism of bioactive epoxygenated fatty acids. In this
mini-review, we discuss the mounting evidence associating sEH with ocular diseases
and its therapeutic value as a target. Substantial data link sEH with the retinal and
choroidal neovascularization underlying diseases such as wet age-related macular
degeneration, retinopathy of prematurity, and proliferative diabetic retinopathy, although
some conflicting results pose challenges for the synthesis of a common mechanism.
sEH also shows therapeutic relevance in non-proliferative diabetic retinopathy and
diabetic keratopathy, and sEH inhibition has been tested in a uveitis model. Various
approaches have been implemented to assess sEH function in the eye, including
expression analyses, genetic manipulation, pharmacological targeting of sEH, and
modulation of certain lipid metabolites that are upstream and downstream of sEH. On
balance, sEH inhibition shows considerable promise for treating multiple eye diseases.
The possibility of local delivery of inhibitors makes the eye an appealing target for future
sEH drug development initiatives.
Keywords: soluble epoxide hydrolase, small molecule inhibitor, age-related macular degeneration, diabetic
retinopathy, diabetic keratopathy, uveitis, angiogenesis
INTRODUCTION
Visual impairment and blindness from ocular diseases can profoundly compromise patients’
quality of life, and imposes a substantial economic burden of $35.4 billion per year in the
United States (Rein et al., 2006). The development of anti-vascular endothelial growth factor
(anti-VEGF) therapies has advanced treatment for neovascular eye diseases, but these drugs have
drawbacks and there is a lack of pharmacotherapies for other ocular diseases (Figure 1A) despite
consistent and intense expansion in market potential for ocular therapeutics (Kompella et al., 2010).
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Understanding the mediators involved in pathophysiology and
identification of therapeutic targets and inhibitors are necessary
in order to address these unmet therapeutic needs.
There is a growing awareness of the importance of bioactive
lipid metabolism to ocular structure, function, and pathology.
Especially, the unique lipid profile of the retina gives an outsized
role for docosahexaenoic acid (DHA, 22:6 ω-3) and DHA-
derived polyunsaturated fatty acid (PUFA) metabolites in the
eye (Figure 1B). DHA is a major structural component of the
membrane phospholipids in the retina (Querques et al., 2011),
constituting 50–60% of the total fatty acids in the outer segments
of photoreceptors (Stinson et al., 1991; Bush et al., 1994; Stillwell
and Wassall, 2003), in contrast to most tissues that contain
only a small portion (∼5%) of their fatty acids as DHA. In
parallel with the arachidonic acid (ARA, 20:4 ω-6) cascade,
the metabolism of DHA involves three branches of oxylipin
synthesis enzymes: cyclooxygenase (COX), lipoxygenase (LOX),
and cytochrome P450 (CYP) epoxygenases, of which the CYPs
are responsible for generating bioactive epoxygenated fatty acids
(EpFAs) (Morisseau et al., 2010; Zhang et al., 2013; Malamas
et al., 2017). EpFAs like epoxyeicosatrienoic acids (EETs) fromω-
6 ARA and epoxydocosapentaenoic acids (EDPs) from ω-3 DHA
have garnered much attention in vascular disorders due to their
vasodilatory and anti-inflammatory properties (Ye et al., 2002;
Zhang et al., 2014; Capozzi et al., 2016).
Epoxygenated fatty acids are physiologically unstable because
they are rapidly metabolized, mainly by soluble epoxide hydrolase
(sEH) (Chacos et al., 1983; Figure 1B). sEH, encoded by the
EPHX2 gene, has a C-terminal hydrolase function that acts on
lipid epoxides, plus a poorly studied N-terminal phosphatase
activity (Harris and Hammock, 2013). Inhibition of sEH stabilizes
EpFAs, enhancing their biological activities, which vary among
EpFAs derived from ω-6 and ω-3 PUFAs. EETs and EDPs
have vasodilatory (Oltman et al., 1998; Zhang et al., 2001; Ye
et al., 2002) and analgesic effects, reducing inflammatory pain
(Inceoglu et al., 2008; Morisseau et al., 2010; Wagner et al.,
2014). But they have contradictory effects on angiogenesis:
EETs usually have proangiogenic effects depending on the
experimental context (Pozzi et al., 2005; Michaelis et al., 2008;
Xu et al., 2013), whereas EDPs have antiangiogenic effects
(Zhang et al., 2013; Capozzi et al., 2014; Hasegawa et al.,
2017; Hu et al., 2017). Moreover, sEH mediated metabolism
of EpFAs produces lipid diols like dihydroxydocosapentaenoic
acids (DHDP) (Figure 1B). Thus, sEH inhibition can result in
tissue specific effects by modulating different classes of EpFAs
depending on the abundance of individual PUFAs in the given
tissue.
Genetic manipulation of CYP/sEH expression and small
molecule mediated targeting of sEH have allowed investigation of
the role of EpFAs in eye diseases, in particular diseases mediated
by inflammation and angiogenesis. Through the metabolism of
bioactive EpFAs and production of corresponding diols, sEH
plays a role in the regulation of angiogenesis and inflammation
relevant to the pathogenesis of numerous eye diseases. This mini-
review discusses sEH as a therapeutic target for eye diseases
and the role of PUFA metabolites of CYP and sEH in ocular
neovascularization and other ocular disorders.
sEH AND NEOVASCULAR EYE
DISEASES
Ocular neovascularization (abnormal angiogenesis) is a
prominent feature of blinding eye diseases including proliferative
diabetic retinopathy (PDR), retinopathy of prematurity (ROP),
and neovascular “wet” age-related macular degeneration
(wet AMD) (Das and McGuire, 2003; Figure 1A). The new
blood vessels that form in these diseases are leaky and prone
to rupture, thereby causing vascular leakage, scarring, and
even retinal detachment that can lead to permanent vision
loss (Hageman et al., 2008). Efforts to treat neovascular eye
diseases are hampered by resistance or refractory response
to the current standard of care, anti-VEGF therapies (Lux
et al., 2007). Therefore, identification of novel therapeutic
targets and inhibitors is needed to address the unmet needs
in antiangiogenic treatment. Metabolites of ω-3 PUFAs from
the CYP-sEH pathway are emerging as important mediators of
angiogenesis (Shao et al., 2014; Yanai et al., 2014; Gong et al.,
2016a,b).
EpFAs and Angiogenesis
Epoxydocosapentaenoic acids are anti-angiogenic in vitro: all
the chemically stable EDP regioisomers inhibited VEGF-induced
angiogenesis in a Matrigel plug assay (Zhang et al., 2013). Of
note, 19,20-EDP, which is the least efficient substrate for sEH,
therefore most abundant isomer (Zhang et al., 2014), had no
effect on endothelial cell proliferation but strongly inhibited
human umbilical vein endothelial cell tubular network formation
and migration and weakly inhibited matrix metalloproteinase
2 (MMP-2) activity via a VEGF receptor 2 dependent manner
(Zhang et al., 2013), although the exact mechanism through
which EDPs crosstalk with VEGF signaling remains to be
clarified.
ω-3 EpFAs also have anti-inflammatory and anti-angiogenic
effects in animal models of ocular angiogenesis. Dietary intake
of ω-3 PUFAs but not ω-6 PUFAs reduces murine laser-induced
choroidal neovascularization (L-CNV) (Yanai et al., 2014), a
widely used model in which laser ruptures Bruch’s membrane,
resulting in angiogenesis from the choroid into the subretinal
space. This recapitulates key features of wet AMD and serves as a
model in which to test anti-angiogenic therapies (Lambert et al.,
2013).
Dietary intake of ω-3 PUFAs in mice substantially enhanced
levels of 17,18-epoxyeicosatetraenoic acid (EEQ) and 19,20-EDP
in the serum lipid profile. However, it did not increase levels
of EDPs in the retinal lipid profile. Interestingly, dietary intake
of 17,18-EEQ or 19,20-EDP also suppressed CNV, suggesting
that the protective effect of ω-3 PUFAs against CNV could
be mediated by its downstream epoxy metabolites that are
generated by CYP. In addition, dietary ω-3 PUFAs interfered
with leukocyte invasion into the CNV lesions, while ω-6 PUFA
did not (Yanai et al., 2014). These effects were associated
with anti-inflammatory properties of EpFAs. Specifically, they
modulated leukocyte rolling velocity by changing the expression
of adhesion molecules on the surfaces of leukocytes and in
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FIGURE 1 | Schematic representation of the eye and PUFA metabolism by the CYP-sEH pathway, and effects of sEH inhibition in vivo. (A) Common eye diseases
and associated structures in the human eye. (B) Retina has the highest concentration of ω-3 docosahexaenoic acid of all fatty acids. The regulation of bioactive
epoxygenated fatty acids takes place through production by cytochrome P450 epoxygenase and degradation by soluble epoxide hydrolase (sEH). ω-3 fatty acids
shown; the same pathway acts on ω-6 fatty acids. (C,D) sEH inhibitor SH-11037 dose-dependently suppresses L-CNV lesion volumes. Figure modified from
Sulaiman et al. (2016). (C) Representative imaging data. Optical coherence tomography obtained 7 days post-laser. Yellow arrows highlight regions containing CNV.
Scale bars = 100 µm. Fluorescein angiography images 14 days post-laser and confocal microscopy images for agglutinin-stained CNV lesions 14 days post-laser.
Scale bars = 50 µm. (D) Quantification of CNV lesion volumes from Z-stack images at day 14 using ImageJ software. ∗∗P < 0.01, one-way ANOVA, Tukey’s
post hoc tests, Mean ± SEM, n = 12 eyes/treatment. AMD, age-related macular degeneration; CYP, cytochrome P450 epoxygenase; DR, diabetic retinopathy;
EpFA, epoxygenated fatty acid; FA, fatty acid; PUFA, polyunsaturated fatty acid; ROP, retinopathy of prematurity; sEH, soluble epoxide hydrolase.
the CNV lesions (Hasegawa et al., 2017). In transgenic mice
overexpressing CYP2C8 in endothelial cells, the dietary intake
of ω-3 PUFAs, which increased production of 17,18-EEQ and
19,20-EDP in serum, reduced CNV lesions (Hasegawa et al.,
2017). Likewise, dietary ω-3 PUFAs reduced CNV lesions in
Ephx2−/− mice. These mice also had increased plasma levels of
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17,18-EEQ and 19,20-EDP, since sEH-dependent degradation of
these epoxides into corresponding diols was blocked. In contrast,
dietary ω-3 PUFAs did not confer inhibitory effects on CNV in
mice overexpressing sEH.
The relevance of sEH to CNV was further supported by
our recent study that showed an increase in the expression of
sEH in the eyes of L-CNV mice and human wet AMD patients
(Sulaiman et al., 2018). Interestingly, sEH was upregulated in
the photoreceptors, and ocular enzymatic activity of sEH was
increased upon L-CNV induction in adult mice. The lipid
profile of retina/choroidal tissue of the mice revealed that the
ratio of 19,20-EDP to 19,20-DHDP was significantly reduced
in L-CNV, suggesting enhanced sEH activity (Sulaiman et al.,
2018). In the developing mouse retina, sEH is highly expressed in
Müller glia, and DHDP produced by sEH contributes to retinal
angiogenesis (Hu et al., 2014). Müller glia span the entire retina
radially, providing structural and metabolic support for retinal
neurons (Reichenbach and Bringmann, 2013). The Müller cell
specific knockout of sEH or systemic deletion of sEH significantly
impaired developmental retinal angiogenesis and altered the
retinal lipid profile. The level of 19,20-DHDP was significantly
reduced in the retina of Ephx2−/− mice. Intravitreal injection of
19,20-DHDP rescued impaired retinal angiogenesis in Ephx2−/−
mice. 19,20-DHDP was also found to be a signaling molecule,
downregulating the endothelial Notch signaling pathway by
inhibiting presenilin-1 dependent γ-secretase activity, which is
required for release of the Notch intracellular domain (Hu
et al., 2014). Interestingly, the crosstalk between Notch and
VEGF pathways in angiogenesis has been reported in numerous
studies, where activation of Notch signaling modulates VEGF
signaling (Hellström et al., 2007; Li and Harris, 2009). Given
this, inhibition of sEH not only stabilizes the anti-angiogenic and
anti-inflammatory ω-3 EpFAs, but also inhibits production of
pro-angiogenic DHDP.
Small Molecule sEH Inhibition and
Ocular Angiogenesis
Targeting sEH with small molecule inhibitors effectively
reduces ocular angiogenesis (Table 1). SH-11037, a synthetic
homoisoflavonoid that we developed in cell-based assays and
subsequently identified as an sEH inhibitor (Sulaiman et al.,
2018), effectively blocked key angiogenic properties of human
retinal endothelial cells (HRECs) – proliferation, migration and
tube formation – without inducing cell death (Basavarajappa
et al., 2015). As well, SH-11037 reduced angiogenesis in an
ex vivo choroidal sprouting assay and inhibited developmental
ocular angiogenesis in zebrafish larvae (Sulaiman et al., 2016).
Local application of SH-11037 (1µM) into the eye via intravitreal
injection significantly suppressed CNV lesions (Sulaiman et al.,
2016; Figures 1C,D) and was also effective in reducing retinal
neovascularization in the oxygen-induced retinopathy (OIR)
model (Basavarajappa et al., 2015), in which neonatal mouse pups
are subjected to hyperoxia during their developmental retinal
vascularization, causing ischemia-induced angiogenesis on
return to normoxia (Scott and Fruttiger, 2009; Kim et al., 2016).
Structural, morphological and vascular examination of retina
and electroretinography showed that up to 100 µM intravitreal
SH-11037 does not exert ocular toxicity (Sulaiman et al., 2016).
Excitingly, SH-11037 also synergized with anti-VEGF therapy to
reduce L-CNV (Sulaiman et al., 2016).
Intravitreal injection of other known sEH inhibitors t-AUCB
(1–10 µM) and “compound 7” (10–30 µM) also suppressed
L-CNV lesions (Sulaiman et al., 2018; Table 1). Moreover,
intravitreal 10 µM SH-11037 or t-AUCB treatment effectively
normalized CNV-induced sEH enzymatic activity and increased
the ratio of 19,20-EDP to 19,20-DHDP, indicating that local
pharmacological inhibition of sEH can alter the lipid metabolism
in the eye (Sulaiman et al., 2018). These studies used 6–15 mice
per treatment, plus vehicle injected controls (Basavarajappa et al.,
2015; Sulaiman et al., 2016, 2018), which should be sufficient
to avoid any confounding effects of inflammation, which is a
concern with this delivery route (Chiu et al., 2007). An inhibitory
effect on ocular angiogenesis was also reported for other
routes of administration of sEH inhibitors. Oral administration
of TPPU (1 mg/kg/day) not only reduced CNV lesions and
vascular leakage, but also its coadministration with i.p. injection
of 17,18-EEQ or 19,20-EDP (50 µg/kg/day) potentiated anti-
angiogenic effects on CNV (Hasegawa et al., 2017). In addition,
normal neonatal mice that received i.p. injection of t-AUCB
(2 mg/kg, twice/day) from 1 to 4 days had significantly reduced
retinal vascularization (Hu et al., 2014). Together, these studies
support the therapeutic potential of sEH inhibitors for ocular
neovascularization.
Conflicts and Controversies
However, some studies do not support the finding that sEH
inhibition reduces ocular angiogenesis (Gong et al., 2017).
Shao et al. (2014) found that EDP is pro-angiogenic and
inhibition of CYP epoxygenase rather than sEH reduced
retinal neovascularization in OIR. Systemic overexpression of
the CYP epoxygenase CYP2C8 and downregulation of sEH
expression in the retina of OIR mice were reflected in
the increased and decreased retinal EDP to DHDP ratio,
respectively. Dietary ω-3 PUFAs enhanced OIR-induced retinal
neovascularization in CYP2C8 overexpressing mice and reduced
retinal neovascularization in sEH overexpressing mice. In the
aortic ring assay, DHA had an anti-angiogenic effect which was
abolished by CYP2C8 overexpression, whereas 19,20-EDP alone
had no effect but 19,20-EDP + sEH overexpression reduced
aortic sprouting (Shao et al., 2014). However, the macrovessels
of the aortic ring do not fully recapitulate microvascular features
of the choroid capillaries (Shao et al., 2013).
Panigrahy and colleagues showed that CYP2CJ and CYP2C8
overexpressing mice and Ephx2−/− mice had enhanced corneal
and neonatal retinal vascularization (Panigrahy et al., 2013)
and enhanced tumor dependent corneal angiogenesis (Panigrahy
et al., 2012). CYP2C8 inhibition with montelukast further
inhibited OIR and L-CNV in mice fed with ω-3 and ω-
6 PUFAs, as opposed to sEH inhibition with i.p. injection
of UC1770 (0.3 mg/kg) which enhanced OIR and L-CNV
(Gong et al., 2016a). Also, UC1770 promoted aortic ring and
choroidal sprouting, while montelukast enhanced the anti-
angiogenic effects of DHA on aortic and choroidal sprouting,
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and HREC proliferation, which were all rescued by 19,20-EDP
(Gong et al., 2016a). CYP2C8 inhibition with fenofibrate also
further reduced OIR and L-CNV in animals fed with dietary
ω-3 PUFAs (Gong et al., 2016b). Again, 19,20-EDP reversed
the anti-angiogenic effects of fenofibrate in aortic and choroidal
sprouting, HREC migration, and tube formation, in contrast to
DHA which enhanced fenofibrate’s anti-angiogenic effects (Gong
et al., 2016b). Thus, these studies present conflicting results
regarding sEH as a therapeutic target for ocular angiogenesis.
Reconciling Disparate Findings
There are important factors to consider in attempting to integrate
the conflicting experimental data: stability of EpFAs, routes of
administration of CYP or sEH inhibitors and systemic or local
modulation of sEH/CYP expression, modulation of other lipid
mediator pathways, and experimental design considerations.
First, we cannot conclude that 19,20-EDP promotes ocular
angiogenesis when studies added 19,20-EDP into growth media
without modulating sEH activity in the aortic ring and choroidal
sprouting assay (Gong et al., 2016a,b). Although 19,20-EDP is a
fairly stable isomer, it can be converted into its corresponding
diol 19,20-DHDP by sEH. Co-treatment with an sEH inhibitor
is required to stabilize 19,20-EDP to ascertain that a change in
phenotype is due to 19,20-EDP and to minimize effects from
19,20-DHDP that is generated by sEH activity. Indeed, Hasegawa
et al. (2017) demonstrated greater inhibitory effects on L-CNV
upon oral administration of sEH inhibitor TPPU + 17,18-EEQ
or 19,20-EDP compared to 17,18-EEQ or 19,20-EDP alone.
Additionally, aortic rings from Ephx2−/− mice treated with
19,20-EDP or 17,18-EEQ did not show any effect on angiogenic
sprouting. One explanation for this lack of effect is that the
lipid concentration used (1 µM) (Shao et al., 2014) may be
below the inhibitory threshold; further characterization of dose
dependent effects of these compounds on angiogenesis may be
necessary.
Second, the studies suggesting that inhibition of sEH promotes
ocular angiogenesis employed sEH blockade via constitutive
Ephx2−/− mice (Panigrahy et al., 2013) or oral administration
(Gong et al., 2016b) or systemic i.p. injection of sEH inhibitors
(Gong et al., 2016a). It is difficult to compare such results to
those from tissue specific local targeting of sEH, considering
the potential confounding effect of the blood-retina barrier
(BRB) and the unique retinal lipid profile. To validate sEH
as a key player in ocular angiogenesis, local targeting of
TABLE 1 | Soluble epoxide hydrolase inhibitors tested in ocular disease animal models.
sEH inhibitor (Reference) Routes Dose Model Reference
t-AUCB (UC1471) (Hwang et al., 2007) Oral 2 mg/L Mouse diabetic retinopathy, sEHI in drinking water for 10 months Hu et al., 2017
Intravitreal 1–10 µM Mouse L-CNV, single sEHI injection Sulaiman et al., 2018
Intraperitoneal 2 mg/kg Mouse neonatal retinal angiogenesis, twice a day sEHI injections for
postnatal (P) days 1–4
Hu et al., 2014
Subconjunctival 10 nM Mouse diabetic keratopathy, single sEHI delivery Sun et al., 2018
TPPU (UC1770) (Rose et al., 2010) Intraperitoneal 0.3 mg/kg Mouse OIR, daily sEHI injections from P12-P16 Gong et al., 2016a
Mouse L-CNV, daily sEHI injections from day 0–6
Oral 1 mg/kg Mouse L-CNV, daily sEHI delivery from 3 days before CNV induction to
day 7
Hasegawa et al., 2017
SH-11037 (Basavarajappa et al., 2015) Intravitreal 0.1–
100 µM
Mouse ocular toxicity Sulaiman et al., 2016
1–10 µM Mouse L-CNV, single sEHI injection
Systemic (in
larvae water)
1–10 µM Ocular angiogenesis in zebrafish larvae, sEHI treatment 2–5 days post
fertilization (dpf)
Intravitreal 1 µM Mouse OIR, single sEHI injection Basavarajappa et al.,
2015
“Compound 7” (Shen et al., 2009) Intravitreal 10–30 µM Mouse L-CNV, single sEHI injection Sulaiman et al., 2018
t-TUCB (UC1728) (Hwang et al., 2007) Subcutaneous 3 mg/kg Rabbit LPS-induced uveitis, daily sEHI injections McLellan et al., 2016
GSK2256294A (Podolin et al., 2013) Subconjunctival 10 nM Mouse diabetic keratopathy, single sEHI delivery Sun et al., 2018
L-CNV, laser-induced choroidal neovascularization; LPS, lipopolysaccharide; OIR, oxygen-induced retinopathy; P, postnatal; sEHI, soluble epoxide hydrolase inhibitor.
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sEH (e.g., tissue-specific knockout, intraocular injection, or
topical therapy) is necessary. Moreover, sEH inhibition can
have opposite effects on angiogenesis depending on tissue levels
of fatty acids that are parent to EpFAs. EETs and EDPs are
the most abundant epoxy substrates of sEH in ω-6 ARA
and ω-3 DHA rich tissues, respectively. EETs usually have
proangiogenic effects (Pozzi et al., 2005; Michaelis et al., 2008;
Xu et al., 2013) while EDPs have antiangiogenic effects (Zhang
et al., 2013; Capozzi et al., 2014; Hasegawa et al., 2017; Hu
et al., 2017). Systemic targeting of sEH could accumulate EETs
and their effects on angiogenesis could outweigh those of
EDPs. Conversely, local targeting of sEH in the eye would
predominantly accumulate EDPs since ω-3 DHA is most
enriched in retina (Querques et al., 2011). Likewise, levels of
EDPs are substantially greater than EETs in retina (Hu et al.,
2014).
Third, the studies that showed that DHA delivery and
CYP inhibition are antiangiogenic do not necessarily lead
to the conclusion that downstream EpFA metabolites
are proangiogenic, since CYP inhibition and the resulting
accumulation of DHA could lead to accumulation of metabolites
from the COX and LOX pathway. The dietary intake of DHA
reduced retinal (Connor et al., 2007; Stahl et al., 2010b; Shao
et al., 2014; Gong et al., 2016b) and choroidal neovascularization
(Moghaddam-Taaheri et al., 2011; Gong et al., 2016a,b), but
the inhibition of CYP epoxygenase potentiated the beneficial
effect of DHA against ocular angiogenesis, suggesting that the
resulting accumulation of DHA or reduced generation of EDP
or both are playing a role in ocular angiogenesis. In addition,
the results can also be partially explained by studies that show
DHA derived metabolites of LOX and COX such as resolvins
and neuroprotectin are anti-inflammatory and inhibit retinal
angiogenesis (Connor et al., 2007). It is likely that the beneficial
effects of exogenous DHA plus CYP blockade are mediated by
increasing free DHA that can efficiently compete with ARA
for the two other major metabolic pathways, LOX and COX,
which produce ARA-derived pro-inflammatory metabolites
such as prostaglandins and leukotrienes (Calder, 2010). In
addition, certain COX metabolites from EETs were shown to be
pro-angiogenic (Rand et al., 2017). Even though inhibition of
CYP would reduce the formation of EDP, the effect of increased
DHA leading to reduction in COX/LOX-dependent ARA derived
pro-inflammatory and pro-angiogenic metabolites, and increase
in COX/LOX dependent DHA derived anti-inflammatory
metabolites could outweigh the loss of EDP.
Finally, experimental design factors should be considered.
The ω-3/ω-6 lipid composition of mouse chow can vary
between facilities, potentially influencing findings. Sex differences
in animal models matter, too, given the estrogen dependent
suppression of sEH expression (Yang et al., 2018). This could
possibly reduce the response to sEH loss/inhibition in female
mice whereas response to sEH loss/inhibition could be more
apparent in male mice. Among the studies discussed above,
many did not specify the sex (Connor et al., 2007; Stahl et al.,
2010b; Hu et al., 2014; Shao et al., 2014; Basavarajappa et al.,
2015; Gong et al., 2016a,b) while some studies reported using
male mice (Panigrahy et al., 2012, 2013; Yanai et al., 2014;
Hasegawa et al., 2017) or female mice (Sulaiman et al., 2016,
2018), thus posing a challenge in assessing potential variability
in results due to sex differences. In addition, sex differences
and age are critical factors in the L-CNV model, as aged female
mice (>9 months) develop more severe CNV lesions than age-
matched male mice whereas sex differences are not significant
in younger mice (Gong et al., 2015). Reassuringly, mice at 6–
8 weeks of age were used in all relevant studies (Yanai et al.,
2014; Gong et al., 2016a; Sulaiman et al., 2016, 2018), which
is an ideal age range for the L-CNV model (Gong et al.,
2015). Likewise, all studies showed rigor in use of littermate
controls for the OIR model (Panigrahy et al., 2012; Shao et al.,
2014; Basavarajappa et al., 2015; Gong et al., 2016a,b), which is
important as mice from larger litters with poor postnatal weight
gain develop more severe OIR (Stahl et al., 2010a; Kim et al.,
2016).
NON-PROLIFERATIVE DIABETIC
RETINOPATHY
Soluble epoxide hydrolase has also been implicated in non-
proliferative diabetic retinopathy. This early phase of the
disease is characterized by pericyte loss and increased
vascular permeability, distinct from the late, proliferative
phase characterized by neovascularization (Hammes et al.,
2002; Figure 1A). A recent study (Hu et al., 2017) reveals
that increased retinal expression of sEH and corresponding
production of 19,20-DHDP contribute to the progression
of non-proliferative diabetic retinopathy in hyperglycemic
Ins2Akita mouse retinas and in the retinas and vitreous of human
diabetic patients. Under normal conditions, retinal endothelial
cells are connected by tight junction proteins and supported
by pericytes. During the early phase of diabetic retinopathy,
19,20-DHDP alters the distribution of presenilin 1 in lipid
rafts of the cell membrane, thereby preventing interaction
between presenilin 1 and cadherins and disrupting endothelial
cell to pericyte and endothelial cell-to-cell contacts. Treatment
with sEH inhibitor t-AUCB (Table 1) in drinking water
(2 mg/L) significantly reduced the retinal level of 19,20-DHDP
and normalized vascular defects (reduced pericyte number,
enhanced migration of vascular pericytes to the extravascular
space, increased acellular capillaries and increased vascular
permeability) that were present in the eyes of diabetic mice.
Overexpression of sEH (delivered by intravitreal adenovirus)
in retinal Müller glia increased retinal 19,20-DHDP and
induced retinopathy in non-diabetic mice, highlighting that
sEH may play a causative role in progression of the disease
(Hu et al., 2017). This mechanism – disrupting endothelial
cell junctions of the BRB by sEH-dependent production of
19,20-DHDP – is worth investigating further since defects in
the BRB contribute to other eye diseases (Campochiaro et al.,
1999; Green, 1999). Furthermore, a recent study reported that
sEH inhibitor TPPU reduces fasting glucose level in rats (Minaz
et al., 2018). Given this, the antihyperglycemic effect of sEH
inhibitors in relation to diabetic retinopathy is also worth
exploring.
Frontiers in Pharmacology | www.frontiersin.org 6 February 2019 | Volume 10 | Article 95
fphar-10-00095 February 5, 2019 Time: 17:13 # 7
Park and Corson Soluble Epoxide Hydrolase in Eyes
DIABETIC KERATOPATHY
Diabetic keratopathy is characterized by delayed corneal
epithelial wound healing and epithelial erosion, resulting in a
compromised defense system against corneal injury and infective
agents (Kaji, 2005). sEH is a potential therapeutic target for
diabetic keratopathy, as tested in a mouse model where corneal
erosions develop upon a single corneal debridement wound (Sun
et al., 2018). The expression and enzymatic activity of sEH were
increased in the corneal epithelial cells of streptozotocin-induced
diabetic epithelial unwounded and wounded mice compared
to control mice. Ephx2−/− mice with streptozotocin-induced
diabetes showed an increase in the rate of epithelial wound
healing, decreased sensory nerve degeneration of corneas, and
did not develop diabetes-associated dry eye symptoms. The
loss of sEH also restored wound-induced STAT3 signaling and
heme oxygenase-1 (HO-1) expression that were downregulated
by hyperglycemic conditions. Similarly, sEH inhibition with
subconjunctival 10 nM t-AUCB or clinical candidate inhibitor
GSK2256294A (Table 1) promoted epithelial wound healing and
restored HO-1 expression in diabetic mouse corneas (Sun et al.,
2018).
UVEITIS
Uveitis refers to numerous intraocular inflammatory conditions
often involving the uvea but not limited to this pigmented tissue
layer (Brady et al., 2016; Figure 1A). Inhibition of sEH has
anti-inflammatory effects in different models of inflammation
(Askari et al., 2014; Hasegawa et al., 2017; Zhou et al., 2017).
Given that a specific sEH inhibitor UC1728 (t-TUCB) (Table 1)
had anti-inflammatory and analgesic effects in laminitic horses
(Guedes et al., 2013), with a favorable pharmacokinetic profile
in mice, it was proposed that subcutaneous injection of UC1728
might attenuate lipopolysaccharide (LPS)-induced inflammatory
uveitis in rabbits (McLellan et al., 2016). In this model,
Escherichia coli-derived LPS is injected into the anterior chamber
(intracameral injection), inducing acute inflammation. Contrary
to the hypothesis, treatment with UC1728 (3 mg/kg) was not
efficacious in attenuating this uveitis. However, it is perhaps
premature to conclude that sEH does not play a role in uveitis.
Analysis of sEH expression and lipid profiles in the affected site
may yet reveal sEH involvement that might respond to local
treatment.
CONCLUSION AND FUTURE
DIRECTIONS
Overall, there is strong evidence that stabilization of anti-
inflammatory and anti-angiogenic EpFAs through sEH inhibition
could be promising therapies for eye diseases. The unique
anatomical and physiological features of the eye as a self-
contained unit pose both advantages and disadvantages in drug
discovery and delivery. Unlike other parts of the central nervous
system, the eye is clinically accessible, allowing targeted drug
delivery via routes of topical eye drops or intraocular injections,
thus systemic side effects can be minimized. Conversely,
barriers such as the cornea, blood aqueous-barrier and BRB
hinder drug transport and absorption (Lee and Pelis, 2016).
Therefore, implementing local routes of administration for lipid
metabolites or sEH inhibitors in the eye is crucial, as is exploring
the rich variety of sEH inhibitors that have been developed
both preclinically and clinically (Shen and Hammock, 2012;
Table 1).
Over the past decade, intravitreal anti-VEGF therapy has
significantly advanced the treatment of neovascular eye diseases.
But the only current delivery route for anti-VEGF agents, due to
their large molecular weight, is intravitreal injection. This can be
associated with intraocular inflammation, infection, hemorrhage,
elevation of intraocular pressure, and cataract (Geroski and
Edelhauser, 2000; Falavarjani and Nguyen, 2013), as well as
patient inconvenience. Small molecule sEH inhibitors could
provide advantages over anti-VEGF agents as they might be
administered through non-invasive routes such as eye drops.
Future studies may also reveal certain sEH inhibitors to be
BRB permeable when delivered systemically, considering that a
blood-brain barrier permeable sEH inhibitor, TPPU, has been
characterized (Inceoglu et al., 2013).
Of course, adverse effects are still possible with sEH inhibitors
if administered systemically, or if local delivery results in systemic
exposure. Some of the compounds discussed here (such as TPPU
and t-TUCB) have been tested for target specificity, with minimal
non-specific binding to pharmacologically important proteins,
rendering unexpected adverse effects unlikely (Lee et al., 2014)
Nonetheless, it will also be important to assess the overall risk and
benefit ratio of sEH inhibitors in the eye regardless of specificity.
But polypharmacology can also offer therapeutic benefit: A
COX-2/sEH dual inhibitor has been characterized as a potent
agent against tumor angiogenesis and tumor growth (Wang
et al., 2018). Utilization of such dual inhibitors or combined
treatment of sEH inhibitors with other anti-inflammatory agents
could also provide therapeutic potential against neovascular and
inflammatory eye diseases. Understanding not only the biological
activities of EpFAs and diols, but also the mechanisms by which
they exert their biological effects in the eye is critical to develop
sEH-mediated therapeutic approaches.
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